Nanjing Anji Biosciences has authorized three products to be developed and commercialized in North America.

Recently, Nanjing Anji Biotechnology Co., Ltd. reached a licensing agreement with Amphastar Pharmaceuticals for three products in the PCC stage targeting tumors and age-related macular degeneration. According to the agreement, Amphastar will be responsible for the development and commercialization of the three products in the North American region, while Nanjing Anji Biotechnology will receive a total of $453 million in upfront payments, milestone payments, and sales royalties.